Search Results - "HASINOFF, Brian B"

Molecular Mechanisms of the Cardiotoxicity of the Proteasomal-Targeted Drugs Bortezomib and Carfilzomib by Hasinoff, Brian B., Patel, Daywin, Wu, Xing

“…Bortezomib and carfilzomib are anticancer drugs that target the proteasome. However, these agents have been shown to exhibit some specific cardiac toxicities…”
Get full text

Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib by Hasinoff, Brian B, Patel, Daywin, O'Hara, Kimberley A

“…The anticancer tyrosine kinase inhibitor sunitinib has been shown recently to be cardiotoxic. Using a neonatal rat myocyte model, we investigated various…”
Get more information

Evaluation of Nitrobenzyl Derivatives of Camptothecin as Anti-Cancer Agents and Potential Hypoxia Targeting Prodrugs by Liang, Dinghua, Wu, Xing, Hasinoff, Brian B, Herbert, David E, Tranmer, Geoffrey K

“…As part of our initial efforts into developing a tumor-targeting therapy, C-10 substituted derivatives of a camptothecin analog (SN-38) have been synthesized…”
Get full text

The use of dexrazoxane for the prevention of anthracycline extravasation injury by Hasinoff, Brian B

“…The use of the anthracycline anticancer drugs doxorubicin, daunorubicin, epirubicin and idarubicin sometimes results in accidental extravasation injury and can…”
Get more information

Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy by Martin, Elke, Thougaard, Annemette Vinding, Grauslund, Morten, Jensen, Peter B, Bjorkling, Fredrik, Hasinoff, Brian B, Tjørnelund, Jette, Sehested, Maxwell, Jensen, Lars H

“…Abstract Anthracycline-induced cardiomyopathy is a major problem in anti-cancer therapy. The only approved agent for alleviating this serious dose limiting…”
Get full text

Mechanisms of Myocyte Cytotoxicity Induced by the Multikinase Inhibitor Sorafenib by Hasinoff, Brian B, Patel, Daywin

“…The use of the anticancer multikinase inhibitor sorafenib is associated with cardiac ischemia or infarction and an increase in hypertension. We investigated…”
Get full text

A QSAR study that compares the ability of bisdioxopiperazine analogs of the doxorubicin cardioprotective agent dexrazoxane (ICRF-187) to protect myocytes with DNA topoisomerase II inhibition by Hasinoff, Brian B., Patel, Daywin, Wu, Xing

“…The cardiotoxicity caused by doxorubicin and extravasation injury caused by anthracyclines is reduced by the clinically approved bisdioxopiperazine drug…”
Get full text

A diazirine-based photoaffinity etoposide probe for labeling topoisomerase II by Chee, Gaik-Lean, Yalowich, Jack C., Bodner, Andrew, Wu, Xing, Hasinoff, Brian B.

“…Etoposide is a widely used anticancer drug that targets topoisomerase II, an essential nuclear enzyme. However, despite the fact that it has been in use and…”
Get full text

Progress curve analysis of the kinetics of slow-binding anticancer drug inhibitors of the 20S proteasome by Hasinoff, Brian B.

“…Bortezomib, carfilzomib, ixazomib, oprozomib, and delanzomib are anticancer drugs that target the proteasomal system. Carfilzomib and oprozomib are…”
Get full text

The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity by Hasinoff, Brian B.

“…The use of the new anticancer tyrosine kinase inhibitors (TKI) has revolutionized the treatment of certain cancers. However, the use of some of these results…”
Get full text

The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro by Hasinoff, Brian B., Patel, Daywin

“…Many new targeted small molecule anticancer kinase inhibitors are actively being developed. However, the clinical use of some kinase inhibitors has been shown…”
Get full text

Disulfiram is a slow-binding partial noncompetitive inhibitor of 20S proteasome activity by Hasinoff, Brian B., Patel, Daywin

“…The alcohol abuse drug disulfiram has also been shown to exhibit potent cell growth inhibitory and anticancer activity. While a number of cellular and animal…”
Get full text

Mechanism of the cytotoxicity of the diazoparaquinone antitumor antibiotic kinamycin F by O'Hara, Kimberley A., Wu, Xing, Patel, Daywin, Liang, Hong, Yalowich, Jack C., Chen, Nan, Goodfellow, Valerie, Adedayo, Otunola, Dmitrienko, Gary I., Hasinoff, Brian B.

“…The bacterial metabolite kinamycin F, which is being investigated as a potent antitumor agent, contains an unusual and potentially reactive diazo group, a…”
Get full text

Total Synthesis of Isoprekinamycin:  Structural Evidence for Enhanced Diazonium Ion Character and Growth Inhibitory Activity toward Cancer Cells by Liu, Wei, Buck, Matthew, Chen, Nan, Shang, Muhong, Taylor, Nicholas J, Asoud, Jalil, Wu, Xing, Hasinoff, Brian B, Dmitrienko, Gary I

“…The structurally novel diazobenzo[a]fluorene antibiotic isoprekinamycin (IPK) has been synthesized for the first time employing a Suzuki coupling of a…”
Get full text

The Role of Topoisomerase IIβ in the Mechanisms of Action of the Doxorubicin Cardioprotective Agent Dexrazoxane by Hasinoff, Brian B., Patel, Daywin, Wu, Xing

“…Dexrazoxane is clinically used to reduce doxorubicin cardiotoxicity and anthracycline-induced extravasation injury. Dexrazoxane is a strong catalytic inhibitor…”
Get full text

The Dihydroorotase Inhibitor 5-Aminoorotic Acid Inhibits the Metabolism in the Rat of the Cardioprotective Drug Dexrazoxane and Its One-Ring Open Metabolites by SCHROEDER, Patricia E, PATEL, Daywin, HASINOFF, Brian B

“…Dexrazoxane (ICRF-187) is clinically used as a doxorubicin cardioprotective agent and to prevent anthracycline extravasation injury. It may act by preventing…”
Get full text

Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform by Hasinoff, Brian B, Wu, Xing, Patel, Daywin, Kanagasabai, Ragu, Karmahapatra, Soumendrakrishna, Yalowich, Jack C

“…Pixantrone is a new noncardiotoxic aza-anthracenedione anticancer drug structurally related to anthracyclines and anthracenediones, such as doxorubicin and…”
Get more information

Mechanisms of the Cardiac Myocyte-Damaging Effects of Dasatinib by Hasinoff, Brian B., Patel, Daywin

“…The anticancer drug dasatinib (Sprycel) is a BCR-ABL1-targeted tyrosine kinase inhibitor used in treating chronic myelogenous leukemia that has been shown in…”
Get full text

The cytotoxicity of the anticancer drug elesclomol is due to oxidative stress indirectly mediated through its complex with Cu(II) by Hasinoff, Brian B., Yadav, Arun A., Patel, Daywin, Wu, Xing

“…Elesclomol is an anticancer drug that is currently undergoing clinical trials. Elesclomol forms a strong 1:1 complex with Cu(II) and may exert its anticancer…”
Get full text

The Myocyte-Damaging Effects of the BCR-ABL1-Targeted Tyrosine Kinase Inhibitors Increase with Potency and Decrease with Specificity by Hasinoff, Brian B., Patel, Daywin, Wu, Xing

“…Five clinically approved BCR-ABL1-targeted tyrosine kinase inhibitors (bosutinib, dasatinib, imatinib, nilotinib, and ponatinib) used for treating chronic…”
Get full text